| Q42379001 | A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression |
| Q90010437 | Alterations of T-cell-mediated immunity in acute myeloid leukemia |
| Q101573919 | Cancer cell metabolic reprogramming: a keystone for the response to immunotherapy |
| Q45944767 | Checkpoint inhibition in pediatric hematologic malignancies. |
| Q34655638 | Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells. |
| Q27006179 | Evaluation of current cancer immunotherapy: hemato-oncology |
| Q46182219 | Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells |
| Q38047057 | Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. |
| Q53706033 | Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. |
| Q34043256 | Identification of a variable number of tandem repeats polymorphism and characterization of LEF-1 response elements in the promoter of the IDO1 gene |
| Q89217952 | Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies |
| Q91272360 | Immune control by amino acid catabolism during tumorigenesis and therapy |
| Q38172521 | Immune evasion in acute myeloid leukemia: current concepts and future directions |
| Q34154994 | In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. |
| Q33688517 | Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. |
| Q41326662 | Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells |
| Q37362632 | Indoleamine 2,3-dioxygenase: is it an immune suppressor? |
| Q35506234 | Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival |
| Q90176765 | Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer |
| Q33832446 | Involvement of oxidative stress in the relapse of acute myeloid leukemia |
| Q37522460 | Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases |
| Q41695046 | Mesenchymal Stem Cells in Myeloid Malignancies: A Focus on Immune Escaping and Therapeutic Implications. |
| Q26746104 | Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality? |
| Q33762042 | Metabolic profiling and novel plasma biomarkers for predicting survival in epithelial ovarian cancer |
| Q38097311 | Modulating T regulatory cells in cancer: how close are we? |
| Q48306002 | Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences. |
| Q38664735 | Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? |
| Q26770391 | Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic) |
| Q60301541 | Overexpression of indoleamine 2,3-dioxygenase correlates with regulatory T cell phenotype in acute myeloid leukemia patients with normal karyotype |
| Q89479382 | Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma |
| Q37788635 | Possible roles of excess tryptophan metabolites in cancer |
| Q36652124 | Programmed death-1 checkpoint blockade in acute myeloid leukemia |
| Q35553553 | Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? |
| Q37829355 | Suppression of T-cell responses by tumor metabolites |
| Q55299267 | Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity. |
| Q26775471 | Targeting the indoleamine 2,3-dioxygenase pathway in cancer |
| Q41348806 | The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells. |
| Q41149149 | The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy |
| Q92905230 | Tumor Metabolism as a Regulator of Tumor-Host Interactions in the B-Cell Lymphoma Microenvironment-Fueling Progression and Novel Brakes for Therapy |